Proactive Investors - Run By Investors For Investors

hVIVO says inoculation warrants further development after showing early promise

National Institutes of Health has released part of the data set from a phase I study
The company is developing a vaccine for mosquito-borne diseases

hVIVO PLC (LON:HVO) said its vaccine for mosquito-borne diseases “warrants further development”.

The company made the assertion following the release of partial data from a phase I trial related to safety and humoral response (which relates to the drug’s potential to induce immunity).

hVIVO builds on position of strength in challenge trials

The update on the hVIVO inoculation was released by the National Institutes of Health (NIH), which shared the new information to American Society of Tropical Medicine and Hygiene's annual conference in New Orleans.

"The presentation of these partial preliminary results by NIH at the conference is encouraging regarding safety and immunogenicity responses,” said chairman Trevor Phillips.

“We look forward to seeing the full data when the NIH completes the sample analyses in due course, at which point, a full assessment of the trial results will be possible".

The remaining primary and secondary results from the phase I study “will be evaluated once the full and final data are available”, said hVIVO.

View full HVO profile View Profile

hVIVO PLC Timeline

Related Articles

February 27 2019
The company is a leader for dried flower vaporizers, and a pioneer in cannabis telemedicine and AI technologies
scientists in a lab
January 30 2019
The technology first drew the attention of ChemioCare CEO Pedro Lichtinger years ago while he oversaw Pfizer's global primary care business
knee physio
February 18 2019
Results from an eight-year clinical extension study showed that ChondroMimetic was able to regenerate cartilage to a structural quality almost identical to native cartilage

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use